Subscribe to RSS
Oral Midodrine as an Adjunct in Rapid Weaning of Intravenous Vasopressor Support in Spinal Cord InjuryFunding None.
Background Majority of acute cervical spinal cord injury end up requiring long-term stay in intensive care unit (ICU). During the initial few days after spinal cord injury, most patients are hemodynamically unstable requiring intravenous vasopressors. However, many studies have noted that long-term intravenous vasopressors remain the main reason for prolongation of ICU stay. In this series, we report the effect of using oral midodrine in reducing the amount and duration of intravenous vasopressors in patients with acute cervical spinal cord injury.
Materials and Methods Five adult patients with cervical spinal cord injury after initial evaluation and surgical stabilization are assessed for the need for intravenous vasopressors. If patients continue to need intravenous vasopressors for more than 24 hours, they were started on oral midodrine. Its effect on weaning of intravenous vasopressors was assessed.
Results Patients with systemic and intracranial injury were excluded from the study. Midodrine helped in weaning of intravenous vasopressors in the first 24 to 48 hours and helped in complete weaning of intravenous vasopressors. The rate of reduction was between 0.5 and 2.0 µg/min.
Conclusion Oral midodrine does have an effect in reduction of intravenous vasopressors for patients needing prolonged support after cervical spine injury. The real extent of this effect needs to be studied with collaboration of multiple centers dealing with spinal injuries. The approach seems to be a viable alternative to rapidly wean intravenous vasopressors and reduce duration of ICU stay.
Keywordscervical spine injury - neurogenic shock - neurointensive care - refractory hypotension - spinal cord injury
AIIMS Bhubaneswar Institute ethical committee. T/I-MF/21-22/21.
Article published online:
16 June 2023
© 2023. Asian Congress of Neurological Surgeons. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)
Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India
- 1 Thongprayoon C, Cheungpasitporn W, Harrison AM. et al. Temporal trends in the utilization of vasopressors in intensive care units: an epidemiologic study. BMC Pharmacol Toxicol 2016; 17 (01) 19
- 2 Phillips AA, Krassioukov AV. Contemporary cardiovascular concerns after spinal cord injury: mechanisms, maladaptations, and management. J Neurotrauma 2015; 32 (24) 1927-1942
- 3 Weaver LC, Fleming JC, Mathias CJ, Krassioukov AV. Disordered cardiovascular control after spinal cord injury [Internet]. In: Handbook of Clinical Neurology. Elsevier B.V.; 2012: 213-233 . [cited 2021]. Accessed April 23, 2023 at: https://pubmed.ncbi.nlm.nih.gov/23098715/
- 4 Walters BC, Hadley MN, Hurlbert RJ. et al; American Association of Neurological Surgeons, Congress of Neurological Surgeons. Guidelines for the management of acute cervical spine and spinal cord injuries: 2013 update. Neurosurgery 2013; 60 (CN_suppl_1): 82-91
- 5 Yue JK, Winkler EA, Rick JW. et al. Update on critical care for acute spinal cord injury in the setting of polytrauma. Neurosurg Focus 2017; 43 (05) E19 [cited 2021]
- 6 Wecht JM, Rosado-Rivera D, Weir JP, Ivan A, Yen C, Bauman WA. Hemodynamic effects of L-threo-3,4-dihydroxyphenylserine (Droxidopa) in hypotensive individuals with spinal cord injury. Arch Phys Med Rehabil 2013; 94 (10) 2006-2012
- 7 Furlan JC, Fehlings MG. Cardiovascular complications after acute spinal cord injury: pathophysiology, diagnosis, and management. Neurosurg Focus 2008; 25 (05) E13
- 8 Fehlings MG, Tetreault LA, Wilson JR. et al. A clinical practice guideline for the management of acute spinal cord injury: introduction, rationale, and scope. Global Spine J 2017; 7 (3, Suppl) 84S-94S
- 9 Witiw CD, Fehlings MG. Acute spinal cord injury. J Spinal Disord Tech 2015; 28 (06) 202-210
- 10 Consortium for Spinal Cord Medicine. Early acute management in adults with spinal cord injury: a clinical practice guideline for health-care professionals. J Spinal Cord Med 2008; 31 (04) 403-479
- 11 Zhang Y, Al Mamun A, Yuan Y. et al. Acute spinal cord injury: pathophysiology and pharmacological intervention (Review). Mol Med Rep 2021; 23 (06) 417
- 12 Ruiz IA, Squair JW, Phillips AA. et al. Incidence and natural progression of neurogenic shock after traumatic spinal cord injury. J Neurotrauma 2018; 35 (03) 461-466
- 13 Smith W, Wan H, Much D, Robinson AG, Martin P. Clinical benefit of midodrine hydrochloride in symptomatic orthostatic hypotension: a phase 4, double-blind, placebo-controlled, randomized, tilt-table study. Clin Auton Res 2016; 26 (04) 269-277
- 14 Lacbnit VK. [Treatment of hypotension in general practice with Gutron]. Wien Med Wochenschr 1975; 125 (25–27): 428-431
- 15 Wright RA, Kaufmann HC, Perera R. et al. A double-blind, dose-response study of midodrine in neurogenic orthostatic hypotension. Neurology 1998; 51 (01) 120-124
- 16 Ward CR, Gray JC, Gilroy JJ, Kenny RA. Midodrine: a role in the management of neurocardiogenic syncope. Heart 1998; 79 (01) 45-49
- 17 Schirger A, Sheps SG, Thomas JE, Fealey RD. Midodrine. A new agent in the management of idiopathic orthostatic hypotension and Shy-Drager syndrome. Mayo Clin Proc 1981; 56 (07) 429-433
- 18 McTavish D, Goa KL. Midodrine. A review of its pharmacological properties and therapeutic use in orthostatic hypotension and secondary hypotensive disorders. Drugs 1989; 38 (05) 757-777
- 19 Santer P, Anstey MH, Patrocínio MD. et al; MIDAS Study Group. Effect of midodrine versus placebo on time to vasopressor discontinuation in patients with persistent hypotension in the intensive care unit (MIDAS): an international randomised clinical trial. Intensive Care Med 2020; 46 (10) 1884-1893
- 20 Riker RR, Gagnon DJ. Midodrine administration during critical illness: fixed-dose or titrate to response?. Intensive Care Med 2021; 47 (02) 249-251
- 21 Levine AR, Meyer MJ, Bittner EA. et al. Oral midodrine treatment accelerates the liberation of intensive care unit patients from intravenous vasopressor infusions. J Crit Care 2013; 28 (05) 756-762
- 22 Whitson MR, Mo E, Nabi T. et al. Feasibility, utility, and safety of midodrine during recovery phase from septic shock. Chest 2016; 149 (06) 1380-1383
- 23 Poveromo LB, Michalets EL, Sutherland SE. Midodrine for the weaning of vasopressor infusions. J Clin Pharm Ther 2016; 41 (03) 260-265
- 24 Rizvi MS, Nei AM, Gajic O, Mara KC, Barreto EF. Continuation of newly initiated midodrine therapy after intensive care and hospital discharge: a single-center retrospective study. Crit Care Med 2019; 47 (08) e648-e653